Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
2012 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, Vol. 53, no 9, 1699-1705 p.Article in journal (Refereed) Published
Thirty-eight adult patients with chronic lymphocytic leukemia (CLL) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplant (allo-SCT) in Sweden between 1999 and 2007. The cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD were 29% and 47%, respectively. Rates of non-relapse mortality, progression-free survival (PFS) and overall survival (OS) were 18%, 47% and 74% at 1 year, and 21%, 25% and 45% at 5 years, respectively. T-cell chimerism after transplant was measured in 31 out of 34 patients (91%) surviving beyond day + 100. Seventeen patients achieved andgt; 90% donor T-cell engraftment at 3 months after allo-SCT and, compared with the 12 patients with andlt;= 90% donor T-cell engraftment, they showed favorable PFS at 1 year (82% vs. 33%, p = 0.002) and better long-term PFS and OS (p = 0.002 and 0.046, respectively). Donor T-cell engraftment of andgt; 90% at 3 months after RIC allo-SCT for CLL seems to predict favorable short-term and long-term outcome.
Place, publisher, year, edition, pages
Informa Healthcare , 2012. Vol. 53, no 9, 1699-1705 p.
Allogeneic stem cell transplant, chronic lymphocytic leukemia, T-cell, donor engraftment
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-82050DOI: 10.3109/10428194.2012.666661ISI: 000307301500012OAI: oai:DiVA.org:liu-82050DiVA: diva2:558003